

Radiačná ochrana Kritériá spôsobilosti laboratórií používajúcich pri biologickej dozimetrii cytokinetickú blokovú mikronukleovú skúšku (CBMN) v periférnych krvných lymfocytoch (ISO 17099: 2024)

STN EN ISO 17099

40 1406

Radiological protection - Performance criteria for laboratories using the cytokinesis-block micronucleus (CBMN) assay in peripheral blood lymphocytes for biological dosimetry (ISO 17099:2024)

Táto norma obsahuje anglickú verziu európskej normy. This standard includes the English version of the European Standard.

Táto norma bola oznámená vo Vestníku ÚNMS SR č. 09/24

Obsahuje: EN ISO 17099:2024, ISO 17099:2024

Oznámením tejto normy sa ruší STN EN ISO 17099 (40 1406) z marca 2018

139131

EUROPEAN STANDARD NORME EUROPÉENNE EUROPÄISCHE NORM

EN ISO 17099

June 2024

ICS 13.280

Supersedes EN ISO 17099:2017

English Version

Radiological protection - Performance criteria for laboratories using the cytokinesis-block micronucleus (CBMN) assay in peripheral blood lymphocytes for biological dosimetry (ISO 17099:2024)

Radioprotection - Critères de performance pour les laboratoires pratiquant la dosimétrie biologique par l'analyse des micronoyaux par blocage de la cytodiérèse (CBMN) dans les lymphocytes du sang périphérique (ISO 17099:2024)

Strahlenschutz - Leistungskriterien für Laboratorien, die den Zytokineseblock-Mikronukleustest (CBMN) in peripheren Blutlymphozyten für die biologische Dosimetrie verwenden (ISO 17099:2024)

This European Standard was approved by CEN on 24 June 2024.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION COMITÉ EUROPÉEN DE NORMALISATION EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

EN ISO 17099:2024 (E)

Contents	Page
European foreword	3

EN ISO 17099:2024 (E)

European foreword

This document (EN ISO 17099:2024) has been prepared by Technical Committee ISO/TC 85 "Nuclear energy, nuclear technologies, and radiological protection" in collaboration with Technical Committee CEN/TC 430 "Nuclear energy, nuclear technologies, and radiological protection" the secretariat of which is held by AFNOR.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by December 2024, and conflicting national standards shall be withdrawn at the latest by December 2024.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

This document supersedes EN ISO 17099:2017.

Any feedback and questions on this document should be directed to the users' national standards body/national committee. A complete listing of these bodies can be found on the CEN website.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and the United Kingdom.

Endorsement notice

The text of ISO 17099:2024 has been approved by CEN as EN ISO 17099:2024 without any modification.



International Standard

ISO 17099

Second edition 2024-06

Radiological protection —
Performance criteria for
laboratories using the cytokinesisblock micronucleus (CBMN) assay
in peripheral blood lymphocytes for
biological dosimetry

Radioprotection — Critères de performance pour les laboratoires pratiquant la dosimétrie biologique par l'analyse des micronoyaux par blocage de la cytodiérèse (CBMN) dans les lymphocytes du sang périphérique



COPYRIGHT PROTECTED DOCUMENT

© ISO 2024

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office CP 401 • Ch. de Blandonnet 8 CH-1214 Vernier, Geneva Phone: +41 22 749 01 11 Email: copyright@iso.org Website: www.iso.org

Published in Switzerland

Contents				
Fore	word		v	
Intr	oductio	n	vii	
1	Scop	e	1	
2	Norn	native references	1	
3	Term	ns and definitions	1	
4		CMBN assay methodology used in this document		
	4.1	General	3	
	4.2	Requests for analysis and blood sampling		
5	Resp	onsibility of the requestor	3	
6	_	onsibility of the service laboratory		
	6.1 6.2	Setup and sustainment of the quality assurance programResponsibility during service		
7		identiality of personal information		
/	7.1	Overview		
	7.2	Applications of the principle of confidentiality	5	
		7.2.1 Delegation of responsibilities within the laboratory7.2.2 Requests for analysis		
		7.2.2 Requests for analysis		
		7.2.4 Anonymity of samples	6	
		7.2.5 Reporting of results 7.2.6 Storage		
		7.2.7 Data security plan		
8	Laboratory safety requirements			
	8.1	Overview	6	
	8.2	Microbiological safety requirements		
	8.3 8.4	Chemical safety requirementsOptical safety requirements		
	8.5	Safety plan		
9	Sample processing		8	
		Culturing		
	9.2 9.3	Staining		
	9.4	Scoring of slides		
		9.4.1 General		
		9.4.2 Criteria for scoring 9.4.3 Scoring data sheets		
	9.5	Automated analysis		
10	Calibration source(s), calibration curve, and minimum detectable dose			
	10.1	Calibration source(s)	11	
	10.2 10.3	Calibration curveBackground MN frequency		
	10.3	Comparison with the background level: Characterisation of the minimum detectable	12	
		dose	13	
11	Accidental exposure involving few individuals			
	11.1	Procedure for scoring MN in BNCs		
		11.1.2 Scoring techniques		
		11.1.3 Laboratory scoring expertise	16	
	11.2	Criteria for converting a MN yield into an estimate of absorbed dose		
		11,4,1 UVCIVICW	TO	

		11.2.2 Comparison with controls	16
		11.2.3 Confidence limits on the number of MN	
		11.2.4 Calculation of absorbed dose for whole-body exposures	
		11.2.5 Calculation of uncertainty on absorbed dose	
		11.2.6 Acute and non-acute exposure cases	
		11.2.7 Testing the distribution of MN per BNC	
		11.2.8 Other exposure scenarios	
	11.3	Reporting of results	
		11.3.1 General	
		11.3.2 Content of the report (see <u>Annex D</u> for a standard form)	
		11.3.3 Interpretation of the results	19
12	Popu	ılation triage	19
	12.1	General	
	12.2	Use of a CBMN assay network for large scale exposures	19
	12.3	Procedure for scoring MN in BNCs	20
	12.4	Criteria for converting a MN yield into an estimate of absorbed dose	
	12.5	Reporting of results	20
13	Oual	ity assurance and quality control	20
10	13.1	Overview	
	13.2	Specific requirement	
		13.2.1 General	
		13.2.2 Performance checks by laboratory inter-comparisons	
		13.2.3 Periodical performance check of scorer qualification	
		13.2.4 Performance checks of sample transport integrity	21
		13.2.5 Performance checks of sample integrity by service laboratory	
		13.2.6 Performance checks for instrumentation	21
		13.2.7 Performance checks of sample protocol	
		13.2.8 Performance checks of sample scoring	
		13.2.9 Performance checks of dose and confidence limits estimation	
		13.2.10 Performance checks for result report generation	22
Anne	x A (in	formative) Sample data sheet for recording MN in BNCs	23
Anne	x B (in	formative) Instructions for requestor (sample)	24
Anne	x C (in	formative) Sample questionnaire	25
Anne	x D (in	formative) Sample of report for single assessment	27
Anne	x E (in	formative) Sample group report	29
Anne	x F (in	formative) Decision threshold and detection limit	31
Biblio	graph	ıy	34

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO document should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

ISO draws attention to the possibility that the implementation of this document may involve the use of (a) patent(s). ISO takes no position concerning the evidence, validity or applicability of any claimed patent rights in respect thereof. As of the date of publication of this document, ISO had not received notice of (a) patent(s) which may be required to implement this document. However, implementers are cautioned that this may not represent the latest information, which may be obtained from the patent database available at www.iso.org/patents. ISO shall not be held responsible for identifying any or all such patent rights.

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 85, *Nuclear energy, nuclear technologies, and radiological protection,* Subcommittee SC 2, *Radiological protection,* in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 430, *Nuclear energy, nuclear technologies and radiological protection,* in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

This second edition cancels and replaces the first edition (ISO 17099:2014), which has been technically revised.

The main changes are as follows:

- minor edits to text throughout;
- reorganization of document to better harmonize with other biological dosimetry standards;
- addition of <u>7.2.7</u> on data security plan;
- additional requirements added for the report on the conditions of the exposure for the calibration curve in <u>10.2</u>;
- relaxation of the number of individuals required for each age group for establishing background micronucleus frequency, leaving the determination up to the head of the laboratory (10.3);
- addition of details on determining the minimal resolvable dose (10.4), the absorbed dose (11.2.4) and the uncertainty (11.2.5);
- removal of reference to coefficient of variance when determining scoring expertise, focussing on the use of 95 % confidence intervals to determine expertise (11.1.3);
- addition of reference to other exposure scenarios (11.2.8);
- removal of Annex on automated micronuclei scoring as it was deemed outside of the scope of the standard;
- addition of a sample group report (see <u>Annex E</u>);

— addition of a detailed annex (see <u>Annex F</u>) for calculating the decision threshold and detection limit along with a sample calculation and R script for performing these calculations.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

The purpose of this document is to define the use of the cytokinesis-block micronucleus (CBMN) assay with human peripheral blood lymphocytes for biological dosimetry of exposure to ionizing radiation. This assay is intended to be applied for accidental or malevolent exposures involving

- a) up to a few casualties to provide individual whole-body dose estimates, or
- b) in a triage mode to populations to provide rapid, lower accuracy dose estimates for individuals that can be improved with more accurate analysis at a later time.

The CBMN assay is an alternative cytogenetic technique, which is possibly simpler and faster to perform than the dicentric assay[1][2]. It is also routinely used to demonstrate exposure to genotoxic agents, other than ionizing radiation, which is not covered in this document. Although culture of the blood samples is slightly longer than for dicentrics, the scoring of micronuclei (MN) in binucleated lymphocytes is easier.

As was done with the dicentric assay, the CBMN assay has been adapted for the emergency triage of large-scale multi-casualty nuclear or radiological incident. The blood volume required for a sufficient number of scorable binucleated cells (BNCs) is similar to that required for the dicentric assay. Again, the faster counting speed for MN compensates for the extended culture time. However, it has to be considered that factors such as age, sex, diet and environmental mutagens can have an influence on the results particularly after low dose exposures[3][4][5]. In addition, the CBMN assay can be performed in an automated mode using various cytometric technologies but these are outside the scope of this document.

This document provides a guideline on how to perform the CBMN assay for dose assessment using documented and validated procedures. Dose assessment using the CBMN assay has relevance in medical management, radiation-protection management, record keeping, and medical/legal requirements. This document is divided into two parts, according to the use of CBMN assay: radiation exposure of a few individuals or population triage in a large radiological or nuclear event.

A part of the information in this document is contained in other international guidelines and scientific publications, primarily in the International Atomic Energy Agency's (IAEA) technical reports series on biological dosimetry. However, this document expands and standardizes the quality assurance and quality control, the criteria of accreditation and the evaluation of performance. This document is generally in conformity with ISO/IEC 17025^[6] with particular consideration given to the specific needs of biological dosimetry. The expression of uncertainties in dose estimations given in this document complies with ISO/IEC Guide 98-3^[15] (former GUM) and the ISO 5725 (all parts)^[7].

Radiological protection — Performance criteria for laboratories using the cytokinesis-block micronucleus (CBMN) assay in peripheral blood lymphocytes for biological dosimetry

1 Scope

This document gives guidance on

- a) confidentiality of personal information for the customer and the laboratory,
- b) laboratory safety requirements,
- c) calibration sources and calibration dose ranges useful for establishing the reference dose-response curves that contribute to the dose estimation from CBMN assay yields and the detection limit,
- d) performance of blood collection, culturing, harvesting, and sample preparation for CBMN assay scoring,
- e) scoring criteria,
- f) conversion of micronucleus frequency in BNCs into an estimate of absorbed dose,
- g) reporting of results,
- h) quality assurance and quality control, and
- i) informative annexes containing sample instructions for customers, sample questionnaire, a microscope scoring data sheet, and a sample report.

This document excludes methods for automated scoring of CBMN.

2 Normative references

There are no normative references in this document.

koniec náhľadu – text ďalej pokračuje v platenej verzii STN